Over 20 years of experience in R&D

01 Drug Discovery

Chemistry Research

Biology Research

Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates

Active Pharmaceutical Ingredients

Pharmaceutical preparation

Analytical Method Development and Quality Control

CMC Filings

Analytical Testing Center

03 Preclinical Research

Pharmacology & Pharmacodynamics

Drug Safety Evaluation

DMPK

Bioanalysis

IND Filings

01 One-stop Integrated Services

Drug Discovery Platform

Pharmaceutical Research Platform

Preclinical Research Services

Botanical Drug Preclinical R&D Technology Platform

02 Innovative Drug Services

ADC R&D Service Platform

PROTAC R&D Service Platform

mRNA Vaccine Bioanalysis Platform

Non-clinical Research for Cellular Immunotherapies

Nucleic Acid Drug R&D Platform

Peptide Drug Conjugate (PDC) R&D Service Platform

Antibody R&D Service

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Platform

Metabolite Identification (MetID) Service Platform

Drug Forming Research Platform

Flow Cytometry Technology Platform

SEND Format Conversion Platform

Flow Sorting Platform

NanoString nCounter Detection Platform

Routes of Drug Administration Platform

04 Drug Efficacy Evaluation for Common Diseases

IO Pharmacodynamic Model Evaluation Platform

Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

05 Advanced Preparation R&D

Inhalation drug R&D platform

Ophthalmic drug R&D platform

Skin Topical Preparation R&D Platform

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service

GLP-1 New Drug R&D Service

KRAS-targeted Drugs R&D Service

2024-07-22Medicilon Events

The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together

On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.

Learn more

2024-07-22Medicilon Events

5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"

Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER

Intellectual Property Protection

U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Shanghai Public Network Security File No. 31011502018888 | Website Map

Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor

2022-04-19

Page View：

Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Christopher Stewart, DABT as the Senior Scientific Advisor of Medicilon. Dr. Stewart will assist the Medicilon scientific research team to better provide tailored comprehensive preclinical R&D services for international pharmaceutical R&D partners.

Dr. Christopher Stewart (2).jpg

Dr. Christopher Stewart, DABT as Senior Scientific Advisor

Dr. Christopher Stewart, Postdoctoral Fellow in Toxicology, University of Arkansas School of Medicine; fellow of the American College of Toxicology and fellow of the Society of Toxicology, with over 30 years of professional experience. Dr. Stewart is currently the Principal Consultant of SGI Consulting. He has worked in research management for MPI Research, the world's largest preclinical CRO, Charles River Laboratories, Arkansas Children's Hospital, and the US FDA. He has extensive practice and deep insights into GLP regulations (including FDA, EPA, OECD and JMHLW) and ICH, and has made great achievements in the field of biomedical development. Dr. Stewart also participated in the preparation of more than 300 global application filing documents, and made positive contributions to the registration of chemical drugs and biological preparations, and the development of new drugs.

It is worth mentioning that SGI Consulting, where Dr. Stewart works, provides a wide range of non-clinical, clinical, chemical and regulatory services for global new drug R&D companies and institutions, but not limited to non-clinical project design of biopharmaceuticals and small molecules, Translational toxicology support and interpretation, regulatory training, regulatory communications, regulatory submissions, referral services, and API manufacturing and clinical support.

Dr Christopher Stewart said, "I have known and assisted Medicilon Nonclinical for many years. Now, it is my pleasure to officially join the team and provide additional support."

Dr. Chunlin Chen, Founder and CEO of Medicilon, said, "I am very excited to have Dr. Christopher Stewart to join Medicilon, As a key opinion leader in the biopharmaceutical field. Dr. Stewart has rich professional experience and extensive resources, and will provide guidance and scientific decision support for Medicilon, which will bring vital assistance to the development of Medicilon to the next stage."

email:marketing@medicilon.com

Senior-Scientific-Advisor

Return

Relevant news